Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article highlights differences in childhood alopecia areata compared to adult cases but reports no new clinical findings.

Children's hair loss has many causes and requires careful diagnosis and personalized treatment, including emotional support.

The document concludes that hair analysis is not good for assessing nutrition but can detect long-term heavy metal exposure.

This review discusses various treatment options for alopecia areata, noting a lack of consensus on grading and treatment algorithms, and reports no new clinical results.

This review discusses the use of phosphodiesterase inhibitors for alopecia, finding promising preliminary results with topical caffeine for androgenetic alopecia and telogen effluvium, but limited success in alopecia areata.

This study found that topical betamethasone dipropionate was more effective than topical latanoprost in reducing the area and promoting hair regrowth in patients with localized alopecia areata, though latanoprost was considered safer.

This study found that treating patchy alopecia areata with fractional CO2 laser and topical triamcinolone acetonide was more effective and safer than intralesional triamcinolone, despite higher initial discomfort, as it resulted in greater patient satisfaction and fewer adverse effects like skin atrophy.

This review evaluates laser therapy for alopecia areata, noting that fractional lasers facilitate hair growth and drug delivery, but reports no new clinical results.

This Cochrane Review protocol aims to evaluate the effectiveness and safety of various treatments for alopecia areata through a network meta-analysis, but no specific study findings are reported yet.

This review discusses various treatment options for Alopecia Areata, focusing on both medical and psychological approaches, and reports no new clinical results.

This case series described five patients with chronic alopecia areata who successfully maintained long-term disease control using a combination of topical immunotherapy and other treatments over 9–15 years, highlighting the approach's continued value alongside novel therapies.

The study found that both mometasone and calcipotriol ointments effectively reduced alopecia severity in localized alopecia areata, with calcipotriol having fewer side effects, while tacrolimus showed no significant effect.

This Delphi study found that moderate-to-severe alopecia areata in Poland, Czechia, Russia, and Türkiye significantly impacts quality of life and highlights an unmet need for more effective treatments.

This study analyzed data from 2083 patients with alopecia areata in Europe and found that those with atopic, autoimmune, or psychiatric comorbidities encountered more severe disease and were more likely to require advanced treatments compared to those without comorbid conditions.

In this nonrandomized controlled study, topical betamethasone dipropionate lotion was found to be significantly more effective for hair regrowth in patients with alopecia areata compared to topical minoxidil solution, with 74% showing efficacy versus 42%, respectively.

This study observed that patient-physician alignment on alopecia areata severity largely followed Japanese Dermatological Association criteria, yet alignment on treatment satisfaction was lower, with lack of efficacy as the main dissatisfaction reason.

This literature review reports that treatments for alopecia areata, including topical and intralesional corticosteroids, provide varied responses, and emphasizes the importance of supporting patients emotionally, given the limited and promising evidence of effectiveness for other treatments.

This review examines current treatments for alopecia areata, noting that topical corticosteroids are commonly used first in children, while more advanced cases may require systemic therapies to modulate the immune system; it reports no new clinical results.

This case report details a 37-year-old woman with alopecia areata who experienced significant hair regrowth after psychological stress-triggered hair loss, following treatment with topical corticosteroids and tofacitinib.

Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.

This study examines the use of diphenylcyclopropenone in treating alopecia areata patients at the University Hospital Würzburg and investigates how the treatment affects patients' quality of life.

This study reports that topical pumpkin seed oil and sesame oil were both effective in treating alopecia areata, with no significant difference in effectiveness between the two after three months.

This chapter reviews traction alopecia, discusses its clinical presentation and severity grading, and reports no new clinical results; the authors highlight controversies in its treatment and prevention strategies.

Alopecia areata is relatively common in children, has a variable course, and shows different responses to treatment; thyroid testing is recommended for those affected.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

A girl with Crohn's disease developed hair loss from her medication, which improved with treatment but later returned.

This study found that non-ablative and/or ablative fractional lasers promoted hair growth in patients with certain uncommon hair disorders, though effectiveness varied among different conditions.

This systematic review assessed cyclosporine's effectiveness with or without corticosteroids for treating alopecia areata, finding combined therapy more effective and with a lower recurrence rate than monotherapy, especially for severe cases, though results varied by alopecia type.

This study found that combining a potent steroid with a vitamin D analogue may offer more convenient treatment for localized alopecia areata than using a superpotent steroid alone, with comparable efficacy but fewer side effects.

This study found that nanoparticles containing minoxidil and betamethasone improved drug delivery to hair follicles, with lipidic nanoparticles significantly enhancing minoxidil and betamethasone penetration compared to control, making them a promising option for alopecia areata treatment with reduced side effects.